pioneer 5 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial BJD

Melanotan 2 Acetate (MT-2) is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals

Take Back Control of Your Wellness Today

Data from the STEP trials showed that approximately 70% of participants reached their target dose, while some patients achieved meaningful results at intermediate doses like 1.7 mg

Small changes over time can help your provider fine-tune your plan

This paper reports an in situ formed immunotherapeutic bioresponsive gel that controls both local tumour recurrence after surgery and development of distant tumours

At Blue Horizon, we believe that understanding your health requires looking at the bigger picture